The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform
H. Reinauer - One of the best experts on this subject based on the ideXlab platform.
-
Sudden onset of EDTA-dependent Pseudothrombocytopenia after therapy with the glycoprotein IIb/IIIa antagonist c7E3 Fab.
Annals of hematology, 2000Co-Authors: H. Stiegler, Y. Fischer, Stefan Steiner, B. E. Strauer, H. ReinauerAbstract:The development of thrombocytopenia following exposure to the platelet glycoprotein (GP) IIb/IIIa receptor antagonist abciximab (c7E3 Fab, ReoPro) is associated with adverse clinical outcome and excessive bleeding. Pseudothrombocytopenia is an important differential diagnosis in sudden onset of thrombocytopenia in a patient treated with c7E3 Fab. We report on a case of documented sudden onset of EDTA-dependent Pseudothrombocytopenia in a 63-year-old woman who was admitted for emergency coronary intervention. Four hours after bolus administration of c7E3 Fab, the platelet concentration in EDTA-anticoagulated blood decreased from 385×109/l to 119×109/l, and it showed a further decrease to 57×109/l at the end of a 12-h infusion. Despite no warnings or abnormalities of the automated cell counter, platelet aggregates were observed by microscopic evaluation of the blood smear. Repeated platelet counts in citrate-anticoagulated samples revealed platelet concentrations within the reference range. EDTA-dependent Pseudothrombocytopenia due to therapy with c7E3 Fab is an important differential diagnosis that needs to be excluded rapidly from other causes of thrombocytopenia to avoid unnecessary further examinations, discontinuation of therapy, or even initiation of inappropriate therapy.
-
sudden onset of edta dependent Pseudothrombocytopenia after therapy with the glycoprotein iib iiia antagonist c7e3 fab
Annals of Hematology, 2000Co-Authors: H. Stiegler, Y. Fischer, Stefan Steiner, B. E. Strauer, H. ReinauerAbstract:The development of thrombocytopenia following exposure to the platelet glycoprotein (GP) IIb/IIIa receptor antagonist abciximab (c7E3 Fab, ReoPro) is associated with adverse clinical outcome and excessive bleeding. Pseudothrombocytopenia is an important differential diagnosis in sudden onset of thrombocytopenia in a patient treated with c7E3 Fab. We report on a case of documented sudden onset of EDTA-dependent Pseudothrombocytopenia in a 63-year-old woman who was admitted for emergency coronary intervention. Four hours after bolus administration of c7E3 Fab, the platelet concentration in EDTA-anticoagulated blood decreased from 385×109/l to 119×109/l, and it showed a further decrease to 57×109/l at the end of a 12-h infusion. Despite no warnings or abnormalities of the automated cell counter, platelet aggregates were observed by microscopic evaluation of the blood smear. Repeated platelet counts in citrate-anticoagulated samples revealed platelet concentrations within the reference range. EDTA-dependent Pseudothrombocytopenia due to therapy with c7E3 Fab is an important differential diagnosis that needs to be excluded rapidly from other causes of thrombocytopenia to avoid unnecessary further examinations, discontinuation of therapy, or even initiation of inappropriate therapy.
Simon Panzer - One of the best experts on this subject based on the ideXlab platform.
-
Heparin-platelet factor (PF) 4 antibodies in patients with Pseudothrombocytopenia: coincidence or association?
Thrombosis and haemostasis, 2000Co-Authors: Ile Schwarzinger, Wolfgang Speiser, Norbert Lubenow, Andreas Greinacher, Simon PanzerAbstract:Heparin-platelet factor (PF) 4 antibodies in patients with Pseudothrombocytopenia : coincidence or association?
-
Documented sudden onset of Pseudothrombocytopenia
Annals of hematology, 1997Co-Authors: M. E. Gschwandtner, Peter Siostrzonek, C. Bodinger, Thomas Neunteufl, Christian Zauner, Gottfried Heinz, Gerald Maurer, Simon PanzerAbstract:A 66-year-old male patient was hospitalized for severe heart failure. Within 3 days after admission his platelet count dropped from 148×109/l to 3×109/l. Pseudothrombocytopenia was diagnosed based on the platelet count of 3×109/l in K3-EDTA anticoagulated blood as opposed to 110×109/l in sodium citrate. Platelet reactive antibodies were not detectable. To the best of our knowledge, this is the first report of a documented onset of Pseudothrombocytopenia.
H. Stiegler - One of the best experts on this subject based on the ideXlab platform.
-
Sudden onset of EDTA-dependent Pseudothrombocytopenia after therapy with the glycoprotein IIb/IIIa antagonist c7E3 Fab.
Annals of hematology, 2000Co-Authors: H. Stiegler, Y. Fischer, Stefan Steiner, B. E. Strauer, H. ReinauerAbstract:The development of thrombocytopenia following exposure to the platelet glycoprotein (GP) IIb/IIIa receptor antagonist abciximab (c7E3 Fab, ReoPro) is associated with adverse clinical outcome and excessive bleeding. Pseudothrombocytopenia is an important differential diagnosis in sudden onset of thrombocytopenia in a patient treated with c7E3 Fab. We report on a case of documented sudden onset of EDTA-dependent Pseudothrombocytopenia in a 63-year-old woman who was admitted for emergency coronary intervention. Four hours after bolus administration of c7E3 Fab, the platelet concentration in EDTA-anticoagulated blood decreased from 385×109/l to 119×109/l, and it showed a further decrease to 57×109/l at the end of a 12-h infusion. Despite no warnings or abnormalities of the automated cell counter, platelet aggregates were observed by microscopic evaluation of the blood smear. Repeated platelet counts in citrate-anticoagulated samples revealed platelet concentrations within the reference range. EDTA-dependent Pseudothrombocytopenia due to therapy with c7E3 Fab is an important differential diagnosis that needs to be excluded rapidly from other causes of thrombocytopenia to avoid unnecessary further examinations, discontinuation of therapy, or even initiation of inappropriate therapy.
-
sudden onset of edta dependent Pseudothrombocytopenia after therapy with the glycoprotein iib iiia antagonist c7e3 fab
Annals of Hematology, 2000Co-Authors: H. Stiegler, Y. Fischer, Stefan Steiner, B. E. Strauer, H. ReinauerAbstract:The development of thrombocytopenia following exposure to the platelet glycoprotein (GP) IIb/IIIa receptor antagonist abciximab (c7E3 Fab, ReoPro) is associated with adverse clinical outcome and excessive bleeding. Pseudothrombocytopenia is an important differential diagnosis in sudden onset of thrombocytopenia in a patient treated with c7E3 Fab. We report on a case of documented sudden onset of EDTA-dependent Pseudothrombocytopenia in a 63-year-old woman who was admitted for emergency coronary intervention. Four hours after bolus administration of c7E3 Fab, the platelet concentration in EDTA-anticoagulated blood decreased from 385×109/l to 119×109/l, and it showed a further decrease to 57×109/l at the end of a 12-h infusion. Despite no warnings or abnormalities of the automated cell counter, platelet aggregates were observed by microscopic evaluation of the blood smear. Repeated platelet counts in citrate-anticoagulated samples revealed platelet concentrations within the reference range. EDTA-dependent Pseudothrombocytopenia due to therapy with c7E3 Fab is an important differential diagnosis that needs to be excluded rapidly from other causes of thrombocytopenia to avoid unnecessary further examinations, discontinuation of therapy, or even initiation of inappropriate therapy.
Nicola Bizzaro - One of the best experts on this subject based on the ideXlab platform.
-
Platelets (Second Edition) - CHAPTER 55 – Pseudothrombocytopenia
Platelets, 2007Co-Authors: Nicola BizzaroAbstract:Pseudothrombocytopenia is a relatively uncommon phenomenon in which the number of platelets reported by automated cell counters is much lower than the real number of platelets circulating in vivo. Awareness of this phenomenon is important because Pseudothrombocytopenia may lead to the erroneous diagnosis of thrombocytopenia, with resultant unnecessary and costly additional laboratory testing, and inappropriate treatment.
Stefan Steiner - One of the best experts on this subject based on the ideXlab platform.
-
Sudden onset of EDTA-dependent Pseudothrombocytopenia after therapy with the glycoprotein IIb/IIIa antagonist c7E3 Fab.
Annals of hematology, 2000Co-Authors: H. Stiegler, Y. Fischer, Stefan Steiner, B. E. Strauer, H. ReinauerAbstract:The development of thrombocytopenia following exposure to the platelet glycoprotein (GP) IIb/IIIa receptor antagonist abciximab (c7E3 Fab, ReoPro) is associated with adverse clinical outcome and excessive bleeding. Pseudothrombocytopenia is an important differential diagnosis in sudden onset of thrombocytopenia in a patient treated with c7E3 Fab. We report on a case of documented sudden onset of EDTA-dependent Pseudothrombocytopenia in a 63-year-old woman who was admitted for emergency coronary intervention. Four hours after bolus administration of c7E3 Fab, the platelet concentration in EDTA-anticoagulated blood decreased from 385×109/l to 119×109/l, and it showed a further decrease to 57×109/l at the end of a 12-h infusion. Despite no warnings or abnormalities of the automated cell counter, platelet aggregates were observed by microscopic evaluation of the blood smear. Repeated platelet counts in citrate-anticoagulated samples revealed platelet concentrations within the reference range. EDTA-dependent Pseudothrombocytopenia due to therapy with c7E3 Fab is an important differential diagnosis that needs to be excluded rapidly from other causes of thrombocytopenia to avoid unnecessary further examinations, discontinuation of therapy, or even initiation of inappropriate therapy.
-
sudden onset of edta dependent Pseudothrombocytopenia after therapy with the glycoprotein iib iiia antagonist c7e3 fab
Annals of Hematology, 2000Co-Authors: H. Stiegler, Y. Fischer, Stefan Steiner, B. E. Strauer, H. ReinauerAbstract:The development of thrombocytopenia following exposure to the platelet glycoprotein (GP) IIb/IIIa receptor antagonist abciximab (c7E3 Fab, ReoPro) is associated with adverse clinical outcome and excessive bleeding. Pseudothrombocytopenia is an important differential diagnosis in sudden onset of thrombocytopenia in a patient treated with c7E3 Fab. We report on a case of documented sudden onset of EDTA-dependent Pseudothrombocytopenia in a 63-year-old woman who was admitted for emergency coronary intervention. Four hours after bolus administration of c7E3 Fab, the platelet concentration in EDTA-anticoagulated blood decreased from 385×109/l to 119×109/l, and it showed a further decrease to 57×109/l at the end of a 12-h infusion. Despite no warnings or abnormalities of the automated cell counter, platelet aggregates were observed by microscopic evaluation of the blood smear. Repeated platelet counts in citrate-anticoagulated samples revealed platelet concentrations within the reference range. EDTA-dependent Pseudothrombocytopenia due to therapy with c7E3 Fab is an important differential diagnosis that needs to be excluded rapidly from other causes of thrombocytopenia to avoid unnecessary further examinations, discontinuation of therapy, or even initiation of inappropriate therapy.
